Pancreas preserving surgery for duodenal gastrointestinal stromal tumor removal.
Minerva Chir
; 71(5): 281-5, 2016 Oct.
Article
en En
| MEDLINE
| ID: mdl-27356148
ABSTRACT
BACKGROUND:
We reported our experience with high-risk, non-metastatic second portion duodenal gastrointestinal stromal tumor (GIST)s in patients who underwent 1-month neoadjuvant cycles with imatinib therapy followed by pancreas-preserving surgery and 12-month of adjuvant chemotherapic regimen including imatinib. This study was conducted to evaluate the short and long-term results.METHODS:
The study was conducted between January 2010 and May 2015. Medical charts and operative logbooks of patients were retrospectively reviewed.RESULTS:
Nine patients form the basis of the current analysis. All patients underwent curative resection with pancreas preservation, and all specimens had histologically negative margins. The median follow-up was 35 months. Eight patients were alive, 1 patient died for myocardial infarction at a mean follow-up of 10 months, 1 patient had a recurrence at a mean follow-up of 32 months and no patients developed distant metastases.CONCLUSIONS:
We are confident to suggest the use of neoadjuvant and adjuvant Imatinib therapy to those patients affected with D2, high-risk, duodenal GISTs to allow a limited resection.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Tumores del Estroma Gastrointestinal
/
Neoplasias Duodenales
/
Duodeno
/
Tratamientos Conservadores del Órgano
Tipo de estudio:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Minerva Chir
Año:
2016
Tipo del documento:
Article